Trump backs psychedelics for mental health in new executive order
US President Donald Trump has signed an executive order focused on accelerating the route of psychedelics to the market, adding…
20 Apr 2026
UCB to purchase Neurona and NRTX-1001 for $1.15bn
UCB has signed a definitive agreement to acquire Neurona Therapeutics in a deal worth up to $1.15bn, adding the latter’s lead asset NRTX-1001 to its epilepsy portfolio. The deal value…
20 Apr 2026
MSD secures EC approval for Enflonsia to prevent infant RSV infection
Merck & Co (MSD) has received the European Commission (EC) approval for Enflonsia (clesrovimab), indicated to prevent respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants during…
17 Apr 2026
Kailera makes history with record-breaking $625m IPO
Obesity biotech Kailera Therapeutics has set its sights on the US public market through an upsized $625m IPO, marking one of the largest public offerings in the sector’s history. In…
17 Apr 2026
Aligos and Xiamen Amoytop sign deal for HBV therapy
Aligos Therapeutics has signed an exclusive licence agreement with Xiamen Amoytop Biotech for the development and commercialisation of pevifoscorvir sodium in Greater China for chronic hepatitis B virus (HBV) infection.…
17 Apr 2026
Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions
Daiichi Sankyo has signed a research partnership with Interna Therapeutics to develop targeted delivery solutions based on molecular nano motor (MNM) technology. The agreement involves Daiichi Sankyo Research Institute Boston…
16 Apr 2026
Developers back Alzheimer’s drugs despite report suggesting lack of efficacy
Eli Lilly and Eisai have backed their Alzheimer’s disease drugs despite research finding the mechanism of action may be less clinically meaningful than suggested. A review by Cochrane found that…